Growth normalizes as Waystar tests its AI cross-sell
- Q2 2026 revenue was $320 million, up 18% year over year, with organic growth at 7%.
- Net revenue retention normalized to 108% for the quarter, returning to historical averages.
- The company saw more than $6 million in bookings from existing clients buying Iodine AI capabilities.
- Provider Solutions remain the core, generating about 75% of revenue with strong unit economics.
- A June 2026 cybersecurity incident exposed limited data, highlighting risks in managing sensitive healthcare information.
AI push meets growth test
Waystar is a healthcare payments software company. Its tools help doctors, clinics, hospitals, and health systems submit claims, fix errors, collect from patients, and get paid faster. That work is boring, but it is vital. If the software fails, cash collection slows.
The bull case rests on high profitability and new product traction. Waystar maintained a 43% adjusted EBITDA margin in Q2 2026 despite doubling capitalized software investments. Early cross-selling of Iodine clinical intelligence generated over $6 million in bookings, proving that clients want these AI tools.
The bear case focuses on slowing top-line momentum. Organic growth decelerated to 7% in Q2 2026, or 10% normalized, as transaction volumes returned to historical growth rates. Net revenue retention also normalized to 108%, down from 110.5% in the prior quarter.
Management is changing during this transition. Alpana Wegner took over as Chief Financial Officer in July 2026. The key test ahead is whether the company can reaccelerate organic growth by pushing AI products into a consolidated hospital market.
Paid when healthcare gets paid
Waystar makes money mainly from recurring subscription fees and volume-based fees. Subscription revenue is steadier. Volume-based revenue rises or falls with the number of claims, statements, or payment workflows that clients run through the platform.
The platform has a data flywheel. Each transaction gives Waystar more data about providers, patients, and payers. The company uses AI and rules-based software to improve automation, reduce errors, and help clients collect more of what they are owed.
Provider Solutions are the better-margin side of the house. Management said they are about 75% of revenue. Patient Payment Solutions are about 25% of revenue and have higher third-party costs, so a mix shift toward Provider Solutions helps margins.
Profitability is a bright spot. Adjusted EBITDA margins hold around 43%. The open question is whether Waystar can keep that margin while funding AI research, integrating Iodine, and defending price in a competitive market.
Claims, patients, and clinical AI
Provider Solutions
These tools help providers manage payer workflows, including claims, denials, and reimbursement tasks. They are about 75% of revenue and have better unit economics than patient payment tools.
Patient Payment Solutions
These products help providers collect money from patients through statements, payment tools, and engagement workflows. The segment is more exposed to transaction volumes and print-to-digital changes.
Clinical integrity and revenue capture
This solution set joins clinical and financial data to find coding mistakes, DRG underpayments, and missing charges. It aims to catch problems before they become denied or underpaid claims.
Iodine clinical intelligence
Iodine adds AI tools for clinical documentation, utilization management, and leakage prevention before billing. The deal expands Waystar deeper into the mid-cycle, where clinical records and payment rules meet.
Prebill anomaly detection
This AI capability looks for unusual issues before a bill goes out. It supports the broader goal of moving from manual repair work to prevention.
Altitude AI recoupment
This newer AI tool helps providers detect hidden payer recoupments, understand root causes, and act using remittance data at scale. Early adoption is an important test for the AI bookings story.
Two revenue pools
Waystar reports as one segment, but management discusses revenue by solution type. Provider Solutions are about 75% of revenue, while Patient Payment Solutions are about 25%.
What could break the story
AI demand fades after early wins
High impact · Medium oddsIf new AI tools do not turn into durable revenue, the Iodine deal may look more like a costly add-on than a platform shift. The company relies on these cross-sells for growth.
Patient payments volume pressure
Medium impact · Medium oddsPatient Payment Solutions are about 25% of revenue and carry higher third-party costs. The segment is highly exposed to transaction volumes and print-to-digital statement conversion headwinds.
NRR slips to historical lows
High impact · Medium oddsNet revenue retention was 108% in Q2 2026, down from 110.5% in the prior quarter. A continued slide would weaken the case that Waystar can keep expanding inside its existing client base.
Cybersecurity and data liability
High impact · Medium oddsA June 2026 cybersecurity incident exposed source code and limited client data. Waystar handles sensitive healthcare data and operates under privacy rules such as HIPAA. Poor AI training data could also create wrong outputs and liability.
Leadership transition execution
Medium impact · Low oddsThe company changed its Chief Financial Officer in July 2026. Executive transitions always carry some risk of disruption in forecasting or strategic execution.
In one breath
What does Waystar do?
Waystar sells cloud software for healthcare payments. Its platform helps providers submit claims, manage denials, improve billing, and collect from patients.
Why is Iodine important to Waystar?
Iodine adds AI-powered clinical intelligence. That helps Waystar find documentation and billing problems before claims are submitted, instead of only fixing payment issues later.
What is net revenue retention for Waystar?
Net revenue retention measures how much existing clients spend now compared with a prior period. Waystar reported 108% for the period ended June 30, 2026.
What is the biggest risk for WAY stock?
The biggest business risk is that organic growth slows once acquisition help and temporary tailwinds fade. Investors should watch net revenue retention and AI bookings.
